205 - Maternal Immunization: A New Era of Prevention of Infant Infection

Wednesday, October 22, 2025

10:30 AM - 11:45 AM US ET

Location: Sidney J. Marcus Auditorium

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-9999-24-002-L01-P
PACE Credits: Maximum of 1 of PACE contact hours
CE Broker: Maximum of 1 CE broker credit hours

Moderator(s)

Flor Munoz, MD

Associate Professor of Pediatrics
Pediatrics
Baylor College of Medicine Houston
Dallas, Texas, United States
Catherine Mary Healy, MD, FIDSA (she/her/hers)

Associate Professor of Pediatrics
Baylor College of Medicine
Houston, TX, United States

Faculty(s)

Janet Englund, MD (she/her/hers)

Dr
Pediatrics
Seattle Children’s Hospital/Univ. Washington
Seattle, WA, United States
Neil Silverman, MD (he/him/his)

Professor of Clinical Obstetrics and Gynecology
David Geffen School of Medicine at UCLA
Los Angeles, CA, United States
Paul Heath, FRCPCH (he/him/his)

Director
Vaccine Institute, Centre for Neonatal and Paediatric Infection, St George’s University of London
London, England, United Kingdom

Disclosure(s):

Flor M. Munoz, MD: Moderna: Board Member; Pfizer: Board Member, Grant/Research Support; Sanofi: Advisor/Consultant

Catherine Mary Healy, MD, FIDSA: Dexcom, Inc: Stocks/Bonds (Public Company); Hillevax, Inc: Advisor/Consultant; Intuitive Surgical, Inc: Stocks/Bonds (Public Company); Quidel Diagnostics: Stocks/Bonds (Public Company); UpToDate Wolters Kluwer Health: Honoraria; Vindico CME: Honoraria

Janet A. Englund, MD: AstraZeneca: Advisor/Consultant, Grant/Research Support; Cidarra: Member Data Safety Monitoring Board; GlaxoSmithKline: Advisor/Consultant, Grant/Research Support; Meissa Vaccines: Advisor/Consultant; Merck: Advisor/Consultant, Grant/Research Support; Pfizer: Advisor/Consultant, Grant/Research Support, Honoraria; Shionogi: Grant/Research Support

Neil Silverman, MD: Cepheid, Inc: Advisor/Consultant; Pfizer, Inc.: Advisor/Consultant, Honoraria

Paul T. Heath, FRCPCH: GSK: Grant/Research Support; MinervaX: Grant/Research Support; Moderna Therapeutics: Grant/Research Support; Pfizer, Inc.: Grant/Research Support

Learning Objectives:

At the conclusion of this session, participants will be able to:

analyze current strategies for prevention of Respiratory Syncytial Virus disease in young infants and their impact;
identify vaccines for the prevention of Group B Streptococcus infection during pregnancy and in neonates;
list key challenges in the implementation of maternal and infant immunization strategies;
explain how specialists can partner to optimize vaccination in pregnancy and early life.

Presentations:

10:30 AM - 10:55 AM US ET

RSV Prevention Strategies During Pregnancy and Early Childhood
Speaker: Janet A. Englund, MD (she/her/hers) – Seattle Children’s Hospital/Univ. Washington
10:55 AM - 11:20 AM US ET

Group B Streptococcus Prevention During Pregnancy and Early Infancy
Speaker: Paul T. Heath, FRCPCH (he/him/his) – Vaccine Institute, Centre for Neonatal and Paediatric Infection, St George’s University of London
11:20 AM - 11:45 AM US ET

Partnering With OBs to Optimize Immunization in Pregnancy and Infancy
Speaker: Neil Silverman, MD (he/him/his) – David Geffen School of Medicine at UCLA